September 16, 2022 4:57pm

Confidence and conviction got lost as 21 of 28 downsizers felt the volume surge/pain while Biostage (BSTG) Pumped/Promoted the volume and pricing +$1.19 with 2,660 shares traded <3-month average = 1,770 shares>

Intellia Therapeutics (NTLA -$2.87) had news of knocked out the gene responsible for a rare and deadly swelling disorder and got dumped while CRIPR Therapeutics (CRSR) showed progress in pre-liminary study and also sunk (-$4.48)

Pre-open indications: 0 HITs, 2 MISS and 1 Pump/Promote  

WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions.  Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

Week in review and nice to be right yet, again!


If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -139.40 points (-0.45%) the S&P closed DOWN -28.02 points (-0.72%) while the Nasdaq closed DOWN -103.95 points (-0.90%)

 

Henry’omics:

Indexes fell Friday heading toward a big losing week, and traders absorbed an ugly earnings warning from FedEx about the global economy.

The three major averages notched their fourth (4th) losing week in five (5).

The Dow has declined -4.1% this week, while the S&P 500 is -5% lower while the Nasdaq is down -5.5%, headed toward its worst weekly loss since June.”

 

RegMed Investor’s (RMi) Pre-Open: “Humpty-Dumpty had a great fall” …  https://www.regmedinvestors.com/articles/12606

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Friday’s advance/decline line opened negative at 34 up/ 0 down and 1 flat, stayed negative at the mid-day with 4 up/31 and 0 flat, ending with a negative close of 6/28 and 1 flat.
  • Thursday’s advance/decline line opened positive at 19 up/ 15 down and 1 flat, flipped negative at 11 a.m. with 14 up/20 and 1 flat cascading positive at the mid-day with 26 up/9 and 0 flat, ending with a positive close of 25/10 and 0 flat.
  • Wednesday’s advance/decline line opened negative at 19 up/ 15 down and 1 flat, flipped positive with 24 up/11 down at the mid-day, ending with a positive close of 24/10 and 1 flat.
  • Tuesday’s advance/decline line opened negative at 2 up/ 31 down and 2 flats, stayed negative with 2 up/32 down and 2 flats at the mid-day, ending with a negative close of 3/32 and 0 flat.
  • Monday’s advance/decline line opened negative at 12 up/ 22 down and 1 flat, stayed negative with 15 up/19 down and 1 flat at the mid-day, ending with a positive close of 21/14 and 0 flat.

 

Pre-open Indications: 0 HITs> 2 MISS < CRISPR Therapeutics (CRSP -$5.43), Intellia Therapeutics (NTLA -$4.29)> and 1 Pump/Promote < Biostage (BSTG +$1.19 with 2,660 shares traded),

 

Key Metrics:

  • Friday - Sector volume was LOW with 4 of the 6-upside having higher than the 3-month average volume with LOW volume of 21 of 28-downside having higher than the 3-month average volume
  • Thursday - Sector volume was LOW with 10 of the 25-upside having higher than the 3-month average volume with LOW volume of 2 of 10-downside having higher than the 3-month average volume
  • Wednesday - Sector volume was LOW with 4 of the 24-upside having higher than the 3-month average volume with LOW volume of 0 of 10-downside having higher than the 3-month average volume
  • Tuesday - Sector volume was LOW with 1 of the 3-upside having higher than the 3-month average volume with LOW volume of 16 of 32-downside having higher than the 3-month average volume
  • Monday - Sector volume was LOW with 7 of the 21-upside having higher than the 3-month average volume with LOW volume of 2 of 14-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB was -0.88% and the XBI was down -3.40%
  • Thursday, the IBB was up +0.13% and the XBI was up +1.30%
  • Wednesday, the IBB was down -0.88% and the XBI was up +1.13%
  • Tuesday, the IBB was down -4.50% and the XBI was down -5.12%
  • Monday, the IBB was up +0.18% and the XBI was up +0.76%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.07 points or -0.27% at 26.20
  • Thursday was up +0.11 points or +0.42% at 26.27
  • Wednesday was down -1.11points or -4.07% at 26.16
  • Tuesday was up +3.40 points or +14.24% at 27.27
  • Monday was up +1.08 points or +4.74% at 23.87

 

Jumping with share pricing momentum (6 of 6):

  • Alnylam Pharmaceuticals (ALNY +$4.52),
  • Biostage (BSTG +$1.19 after Thursday’s -$0.19 after Wednesday’s +$0.15, Tuesday’s -$0.30 and Monday’s -$0.10),
  • Mesoblast (MESO +$0.06),
  • Homology Medicine (FIXX +$0.04 after Thursday’s -$0.13 and Wednesday’s -$0.01),
  • Avrobio (AVRO +$0.0127),
  • Adverum Biotechnologies (ADVM +$0.01),

Closing down (10 of 28):

  • Verve Therapeutics (VERV -$4.95 after Thursday’s +$1.14 and Wednesday’s +$1.84),
  • CRISPR Therapeutics (CRSP -$4.61 after Thursday’s +$2.82, Wednesday’s +$4.64, Tuesday’s -$2.27 and Monday’s +$2.86),
  • Beam Therapeutics (BEAM -$3.93 after Thursday’s +$3.66, Wednesday’s +$3.50 and Tuesday’s -$4.25)
  • Intellia Therapeutics (NTLA -$3.27 after Thursday’s +$4.70, Wednesday’s +$0.73, Tuesday’s -$2.05 and Monday’s +$0.76),
  • BioLife Solutions (BLFS -$3.06 after Thursday’s -$0.170,
  • Sage Therapeutics (SAGE -$2.18 after Thursday’s +$1.09, Wednesday’s +$0.72, Tuesday’s -$1.51 and Monday’s -$0.04),
  • Fate Therapeutics (FATE -$2.02 after Thursday’s +$0.97, Wednesday’s -$3.53 after Monday’s +$1.02),
  • Editas Medicine (EDIT -$1.70 after Thursday’s +$1.43 and Wednesday’s -$0.13),
  • Ultragenyx (RARE -$1.45 after Thursday’s +$2.01, Wednesday’s -$0.54, Tuesday’s -$2.97 and Monday’s -$0.46),
  • Caribou Biosciences (CRBU -$1.36),

 

September, Q3/2022:

  • Friday closed negative with 6 incliners, 28 decliners and 1 flat
  • Thursday closed positive with 25 incliner, 10 decliners and 0 flat
  • Wednesday closed positive with 24 incliner, 10 decliners and 1 flat
  • Tuesday closed negative with 3 incliner, 32 decliners and 0 flat
  • Monday closed positive with 21 incliner, 14 decliners and 0 flat

 

The BOTTOM LINE: The sector ended the day in the RED!

I try to keep it simple … and short!

September continued with 1 holiday, 7 positive and 4 negative closes; August is over with 1 neutral, 11 positive and 11 negative closes while last week which ended the month.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

Start by looking at cell and gene therapy companies trading below cash!” 

Repeating myself, “I find it very interesting to evaluate share price over earnings and a shortage of revenue reporting as a proxy for share pricing performance?”

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.